Abstract
Hypertension is a primary driver of global cardiovascular mortality. While conventional treatments like ACE inhibitors are effective, their side effects necessitate the exploration of alternative therapies. This study investigates the antihypertensive potential of SABP—a combination of aqueous metabolites from Salvia miltiorrhiza Bunge—focusing on its impact on the vascular adventitia. Using Spontaneously Hypertensive Rats (SHRs) and primary adventitial fibroblast cultures, researchers demonstrated that SABP significantly reduces blood pressure. The mechanism involves the inhibition of oxidative stress, inflammation, and fibrosis through the ROS/TLR4/NF-κB and TGFβ/Smad3 signaling pathways. These findings highlight SABP as a promising candidate for treating vascular remodeling in hypertension.
Introduction: Shifting Focus to the Vascular Adventitia
Traditional hypertension research often emphasizes the inner layers of blood vessels, namely the endothelium and media. However, recent evidence suggests the vascular adventitia—the outermost layer—plays a critical role in disease progression. In hypertensive states, adventitial fibroblasts (AFs) transform into myofibroblasts, initiating a cycle of inflammation and fibrosis that increases arterial stiffness.
This study explores whether SABP, an optimized blend of hydrophilic metabolites (DSS, Sal-A, Sal-B, and PAL) from the herb Salvia miltiorrhiza (Danshen), can break this cycle and restore vascular health.
Methodology
The research utilized a dual-track experimental design:
- In Vivo Model: Spontaneously Hypertensive Rats (SHRs) were treated with daily intraperitoneal injections of SABP or perindopril (the positive control) for eight weeks. Blood pressure was monitored weekly via the tail-cuff method.
- In Vitro Model: Primary adventitial fibroblasts were isolated from the thoracic aortas of SHRs and healthy Wistar-Kyoto (WKY) rats to observe cellular responses to SABP treatment.
Advanced imaging and molecular techniques, including Transmission Electron Microscopy (TEM), Western Blotting, and CCK-8 assays, were used to evaluate structural damage and protein expression related to oxidative stress and fibrosis.
Key Findings
Blood Pressure and Structural Recovery
SABP treatment led to a significant reduction in blood pressure. After 6 weeks of treatment, systolic blood pressure (SBP) decreased by approximately 24.9 mmHg and diastolic blood pressure (DBP) by 21.5 mmHg. These results were comparable to the efficacy of the pharmaceutical control, perindopril.
Microscopic analysis via TEM revealed that SABP protected the cellular architecture of the aorta, reducing mitochondrial cristae breakage and decreasing the thickness of the adventitia relative to the total vessel wall.
Molecular Mechanisms of Action
The study identified two primary pathways through which SABP exerts its protective effects:
- Anti-Inflammatory and Antioxidant: SABP inhibited the ROS/TLR4/NF-κB signaling cascade, leading to a reduction in oxidative stress markers (NOX1, NOX2, NOX4) and inflammatory cytokines like IL-6.
- Anti-Fibrotic: By suppressing the TGFβ/Smad3 pathway, SABP prevented the transformation of fibroblasts into myofibroblasts, thereby reducing the deposition of excess collagen (Collagen-I) and connective tissue growth factor (CTGF).
Discussion and Future Directions
The results suggest that the adventitia is a viable therapeutic target for hypertension. SABP's multi-pathway approach—targeting both inflammation and fibrosis—offers a comprehensive strategy for managing vascular remodeling.
While promising, the study notes limitations. The focus on the thoracic aorta should be expanded to smaller resistance vessels in future research. Additionally, the transition from intraperitoneal injection to oral delivery must be evaluated for clinical feasibility. Nonetheless, SABP represents a potent natural alternative for ameliorating the structural and functional damage associated with chronic hypertension.
Summary updated